MYD88 and ulcerative colitis: Ye et al., demonstrated that dexmedetomidine alleviated intestinal barrier dysfunction and inflammation in a mouse model of ulcerative colitis by inhibiting the TLR4/MYD88/NF‐κB signaling pathway.[46] It is well known that the NF‐κB‐MLCK/MLC2 pathway plays a crucial role in regulating intestinal barrier integrity.